Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study

Joseph E. Tota; Frank Struyf; Allan Hildesheim; Paula Gonzalez; Martin Ryser; Rolando Herrero; John Schussler; Naveen Karkada; Ana Cecilia Rodriguez; Nicolas Folschweiller; Carolina Porras; Mark Schiffman; John T. Schiller; Wim Quint; Aimée R. Kreimer; Matti Lehtinen; Cosette M. Wheeler; Joshua N. Sampson

doi:10.1093/infdis/jiaa561

Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study

Joseph E. Tota
, Frank Struyf
, Allan Hildesheim
, Paula Gonzalez
, Martin Ryser
, Rolando Herrero
, John Schussler
, Naveen Karkada
, Ana Cecilia Rodriguez
, Nicolas Folschweiller
, Carolina Porras
, Mark Schiffman
, John T. Schiller
, Wim Quint
, Aimée R. Kreimer
, Matti Lehtinen
, Cosette M. Wheeler
, Joshua N. Sampson

Research output: Contribution to journal › Article › Scientific › peer-review

13 Citations (Scopus)

Abstract

Clinical trial data and real-world evidence suggest that the AS04-adjuvanted vaccine targeting human papillomavirus types 16 and 18 (AS04-HPV-16/18) vaccine provides nearly 90% protection against cervical intraepithelial neoplasia grade 3 or higher irrespective of type, among women vaccinated before sexual debut. This high efficacy is not fully explained by cross-protection. Although AS04-HPV-16/18 vaccination does not affect clearance of prevalent infections, it may accelerate clearance of newly acquired infections. We pooled data from 2 large-scale randomized controlled trials to evaluate efficacy of the AS04-HPV-16/18 vaccine against clearance of nontargeted incident infections. Results of our analysis do not suggest an effect in expediting clearance of incident infections.

Original language	English
Pages (from-to)	1576-1581
Number of pages	6
Journal	Journal of Infectious Diseases
Volume	223
Issue number	9
DOIs	https://doi.org/10.1093/infdis/jiaa561
Publication status	Published - May 2021
Publication type	A1 Journal article-refereed

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

clearance
efficacy
HPV
progression
vaccination

Publication forum classification

Publication forum level 2

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Access to Document

10.1093/infdis/jiaa561

Fingerprint

Dive into the research topics of 'Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study'. Together they form a unique fingerprint.

Cite this

Tota, J. E., Struyf, F., Hildesheim, A., Gonzalez, P., Ryser, M., Herrero, R., Schussler, J., Karkada, N., Rodriguez, A. C., Folschweiller, N., Porras, C., Schiffman, M., Schiller, J. T., Quint, W., Kreimer, A. R., Lehtinen, M., Wheeler, C. M., & Sampson, J. N. (2021). Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study. Journal of Infectious Diseases, 223(9), 1576-1581. https://doi.org/10.1093/infdis/jiaa561

@article{e421dc752ce541d1afe370a0ef737e77,

title = "Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study",

abstract = "Clinical trial data and real-world evidence suggest that the AS04-adjuvanted vaccine targeting human papillomavirus types 16 and 18 (AS04-HPV-16/18) vaccine provides nearly 90\% protection against cervical intraepithelial neoplasia grade 3 or higher irrespective of type, among women vaccinated before sexual debut. This high efficacy is not fully explained by cross-protection. Although AS04-HPV-16/18 vaccination does not affect clearance of prevalent infections, it may accelerate clearance of newly acquired infections. We pooled data from 2 large-scale randomized controlled trials to evaluate efficacy of the AS04-HPV-16/18 vaccine against clearance of nontargeted incident infections. Results of our analysis do not suggest an effect in expediting clearance of incident infections.",

keywords = "clearance, efficacy, HPV, progression, vaccination",

author = "Tota, \{Joseph E.\} and Frank Struyf and Allan Hildesheim and Paula Gonzalez and Martin Ryser and Rolando Herrero and John Schussler and Naveen Karkada and Rodriguez, \{Ana Cecilia\} and Nicolas Folschweiller and Carolina Porras and Mark Schiffman and Schiller, \{John T.\} and Wim Quint and Kreimer, \{Aim{\'e}e R.\} and Matti Lehtinen and Wheeler, \{Cosette M.\} and Sampson, \{Joshua N.\}",

note = "Publisher Copyright: Published by Oxford University Press for the Infectious Diseases Society of America 2020.",

year = "2021",

month = may,

doi = "10.1093/infdis/jiaa561",

language = "English",

volume = "223",

pages = "1576--1581",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "9",

}

Tota, JE, Struyf, F, Hildesheim, A, Gonzalez, P, Ryser, M, Herrero, R, Schussler, J, Karkada, N, Rodriguez, AC, Folschweiller, N, Porras, C, Schiffman, M, Schiller, JT, Quint, W, Kreimer, AR, Lehtinen, M, Wheeler, CM & Sampson, JN 2021, 'Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study', Journal of Infectious Diseases, vol. 223, no. 9, pp. 1576-1581. https://doi.org/10.1093/infdis/jiaa561

Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study. / Tota, Joseph E.; Struyf, Frank; Hildesheim, Allan et al.
In: Journal of Infectious Diseases, Vol. 223, No. 9, 05.2021, p. 1576-1581.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections

T2 - Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study

AU - Tota, Joseph E.

AU - Struyf, Frank

AU - Hildesheim, Allan

AU - Gonzalez, Paula

AU - Ryser, Martin

AU - Herrero, Rolando

AU - Schussler, John

AU - Karkada, Naveen

AU - Rodriguez, Ana Cecilia

AU - Folschweiller, Nicolas

AU - Porras, Carolina

AU - Schiffman, Mark

AU - Schiller, John T.

AU - Quint, Wim

AU - Kreimer, Aimée R.

AU - Lehtinen, Matti

AU - Wheeler, Cosette M.

AU - Sampson, Joshua N.

N1 - Publisher Copyright: Published by Oxford University Press for the Infectious Diseases Society of America 2020.

PY - 2021/5

Y1 - 2021/5

N2 - Clinical trial data and real-world evidence suggest that the AS04-adjuvanted vaccine targeting human papillomavirus types 16 and 18 (AS04-HPV-16/18) vaccine provides nearly 90% protection against cervical intraepithelial neoplasia grade 3 or higher irrespective of type, among women vaccinated before sexual debut. This high efficacy is not fully explained by cross-protection. Although AS04-HPV-16/18 vaccination does not affect clearance of prevalent infections, it may accelerate clearance of newly acquired infections. We pooled data from 2 large-scale randomized controlled trials to evaluate efficacy of the AS04-HPV-16/18 vaccine against clearance of nontargeted incident infections. Results of our analysis do not suggest an effect in expediting clearance of incident infections.

AB - Clinical trial data and real-world evidence suggest that the AS04-adjuvanted vaccine targeting human papillomavirus types 16 and 18 (AS04-HPV-16/18) vaccine provides nearly 90% protection against cervical intraepithelial neoplasia grade 3 or higher irrespective of type, among women vaccinated before sexual debut. This high efficacy is not fully explained by cross-protection. Although AS04-HPV-16/18 vaccination does not affect clearance of prevalent infections, it may accelerate clearance of newly acquired infections. We pooled data from 2 large-scale randomized controlled trials to evaluate efficacy of the AS04-HPV-16/18 vaccine against clearance of nontargeted incident infections. Results of our analysis do not suggest an effect in expediting clearance of incident infections.

KW - clearance

KW - efficacy

KW - HPV

KW - progression

KW - vaccination

U2 - 10.1093/infdis/jiaa561

DO - 10.1093/infdis/jiaa561

M3 - Article

C2 - 32887990

AN - SCOPUS:85107087375

SN - 0022-1899

VL - 223

SP - 1576

EP - 1581

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 9

ER -